At Verisian, we envision a world where groundbreaking treatments are judged using all available evidence and the best tools, where the science is transparent to companies, regulators, and patients alike, and where patients have access to the latest cutting-edge treatments as soon as possible. We’re building innovation for clinical research and public health authorities. While CDISC standards like SDTM and ADaM have brought standardization for clinical trial data, lengthy analysis and submission cycles remain just as increasing trial complexity presents substantial challenges in decision-making and the potential for critical errors. The products we build empower researchers and regulators to analyze and monitor studies transparently in real-time, leading to improved and safer therapies for devastating diseases. Recognizing we cannot do this alone, we're building a community for those who share our commitment and purpose. As we take this journey, we're also expanding our team. If you've done exceptional work, join us in tackling the world's most critical healthcare problem and let's shape the future together.
Employees: 1-10
Total raised: $1.3M
Founded date: 2023
Investors 2
| Date | Name | Website |
| 30.11.2023 | Cambridge ... | cambridgea... |
| 25.10.2023 | SuperSeed | superseed.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.08.2023 | Pre-Seed | $1.3M | - |
Mentions in press and media 1
| Date | Title | Description | Source |
| - | Verisian | “Verisian accelerates drug time to market with the industry's first platform offering real study tra... | fastfounde... |